Tiba Biotech LLC
Cambridge, MA
- UEI
- XNL9ZSLHN795
- CAGE
- 7QLV7
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1 Broadway fl 14, Cambridge, MA 02142, USA
- Website
- tiba.bio
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$23,610 |
| FY2025 | $0 |
| FY2024 | $749,999 |
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| HDT Bio Corp | Seattle, WA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Autonomous Therapeutics Inc. | Silver Spring, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Medigen, Inc. | Frederick, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Neovaxsyn Inc. | Ames, IA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Emmune Inc. | Cambridge, MA | — |
About the company
Tiba Biotech LLC, a Cambridge, Massachusetts-based biotechnology company, develops RNA delivery platforms and vaccine technologies for federal health agencies as a prime recipient on federal research grants and as a prime contractor on R&D development work, competing full-and-open without set-aside designation.
Tiba Biotech operates exclusively as a prime on federal awards (100% of recent activity). The company's core capability is proprietary dendrimer-based nanoparticle systems for non-viral RNA delivery, marketed under the RNABL platform. These systems are engineered to maximize RNA payload content, protect nucleic acids from degradation, facilitate cellular uptake, and enable tissue-targeted delivery with reduced inflammatory burden — positioning the platform as an alternative to lipid nanoparticles for applications where precision delivery and tolerability are critical. The company has applied this platform to respiratory virus treatment, cancer immunotherapy, and pandemic influenza preparedness across multiple federal grants and one contract work.
All four of Tiba Biotech's customer agencies operate under the Department of Health and Human Services umbrella. The National Institute of Allergy and Infectious Diseases (NIAID) has placed four awards: a February 2022 Phase I SBIR grant for rapid-response H7N9 pandemic influenza RNA vaccine development (with ultimate completion October 31, 2022), a February 2022 Phase II grant for the same H7N9 vaccine work (extending through August 31, 2027), and a June 2022 Phase I grant for low-dose Powassan virus RNA vaccine platform development using replicon RNA and dendrimer delivery systems (completed October 31, 2024). The National Cancer Institute awarded a September 2025 SBIR Phase I project grant of $399,300 for targeted delivery of enhanced self-amplifying RNA encoding tumor antigens to the spleen for cancer immunotherapy, with work running through August 31, 2027. The National Heart, Lung, and Blood Institute awarded a Phase I SBIR of $396,805 in August 2026 for lung-targeting siRNA delivery system development, with work in Woburn, Massachusetts through July 31, 2027. The Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $726,389 firm fixed-price contract on April 30, 2024, for R&D of respiratory virus treatment using lung-targeted siRNA delivery systems, scheduled for completion August 5, 2025.
Three awards (combined ultimate completion dates within the next twenty-four months) face recompete exposure: the ASPR contract and two grant projects. The source carries no data on SCI-reportable invoiced revenue or hourly-rate posture; all Tiba awards are research grants or R&D contracts tracked outside standard service contract inventory reporting.
Quick answers
Is Tiba Biotech LLC registered in SAM.gov?
Yes. Tiba Biotech LLC's SAM.gov registration is active through January 27, 2027.
How much has Tiba Biotech LLC received in federal contracts?
Federal contracts obligated $726,389 to Tiba Biotech LLC in fiscal years 2023 through 2027.
What is Tiba Biotech LLC's most recent federal award?
Tiba Biotech LLC's most recent federal grant award is Lung-targeting delivery of small interfering RNA for pulmonary therapeutics - nucleic acid-based interventions have… (R43HL184887), from National Heart Lung and Blood Institute (NIH), on August 1, 2026.
On GovTribe
See Tiba Biotech LLC's full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors